Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB (ISOFOL) - Net Assets
Latest net assets as of December 2025: Skr107.87 Million SEK
Based on the latest financial reports, Isofol Medical AB (ISOFOL) has net assets worth Skr107.87 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr129.40 Million) and total liabilities (Skr21.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr107.87 Million |
| % of Total Assets | 83.37% |
| Annual Growth Rate | 20.54% |
| 5-Year Change | -66.1% |
| 10-Year Change | 1668.68% |
| Growth Volatility | 1582.55 |
Isofol Medical AB - Net Assets Trend (2011–2025)
This chart illustrates how Isofol Medical AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Isofol Medical AB (2011–2025)
The table below shows the annual net assets of Isofol Medical AB from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr107.87 Million | +38.40% |
| 2024-12-31 | Skr77.94 Million | -35.81% |
| 2023-12-31 | Skr121.43 Million | -23.38% |
| 2022-12-31 | Skr158.48 Million | -50.20% |
| 2021-12-31 | Skr318.23 Million | +378.06% |
| 2020-12-31 | Skr66.57 Million | -36.55% |
| 2019-12-31 | Skr104.91 Million | -60.41% |
| 2018-12-31 | Skr265.01 Million | -22.75% |
| 2017-12-31 | Skr343.03 Million | +5524.41% |
| 2016-12-31 | Skr6.10 Million | +361.35% |
| 2015-12-31 | Skr1.32 Million | -83.24% |
| 2011-12-31 | Skr7.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Isofol Medical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 117401552300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr8.61 Million | 7.98% |
| Other Components | Skr1.30 Billion | 1203.91% |
| Total Equity | Skr107.87 Million | 100.00% |
Isofol Medical AB Competitors by Market Cap
The table below lists competitors of Isofol Medical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Painchek Ltd
AU:PCK
|
$13.56 Million |
|
Ynvisible Interactive Inc
OTCQB:YNVYF
|
$13.56 Million |
|
FM Global Logistics Holdings Bhd
KLSE:7210
|
$13.56 Million |
|
Champion Technology Holdings Ltd
PINK:CPIHF
|
$13.56 Million |
|
Earth Tech Environment Public Company Limited
BK:ETC
|
$13.55 Million |
|
LGMS Berhad
KLSE:0249
|
$13.55 Million |
|
Opter AB
ST:OPTER
|
$13.55 Million |
|
Izotropic Corporation
OTCQB:IZOZF
|
$13.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Isofol Medical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 77,945,000 to 107,872,000, a change of 29,927,000 (38.4%).
- Net loss of 54,168,000 reduced equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 84,096,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-54.17 Million | -50.22% |
| Other Comprehensive Income | Skr-1.00K | -0.0% |
| Other Changes | Skr84.10 Million | +77.96% |
| Total Change | Skr- | 38.40% |
Book Value vs Market Value Analysis
This analysis compares Isofol Medical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.46x to 1.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | Skr0.27 | Skr0.66 | x |
| 2015-12-31 | Skr0.04 | Skr0.66 | x |
| 2016-12-31 | Skr0.22 | Skr0.66 | x |
| 2017-12-31 | Skr7.02 | Skr0.66 | x |
| 2018-12-31 | Skr4.70 | Skr0.66 | x |
| 2019-12-31 | Skr1.86 | Skr0.66 | x |
| 2020-12-31 | Skr0.86 | Skr0.66 | x |
| 2021-12-31 | Skr2.53 | Skr0.66 | x |
| 2022-12-31 | Skr0.98 | Skr0.66 | x |
| 2023-12-31 | Skr0.75 | Skr0.66 | x |
| 2024-12-31 | Skr0.48 | Skr0.66 | x |
| 2025-12-31 | Skr0.50 | Skr0.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Isofol Medical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.20x
- Recent ROE (-50.22%) is above the historical average (-421.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -134.42% | 0.00% | 0.00x | 1.32x | Skr-11.39 Million |
| 2015 | -3077.84% | -21758.82% | 0.02x | 7.40x | Skr-40.82 Million |
| 2016 | -1049.65% | -12601.97% | 0.02x | 3.75x | Skr-64.63 Million |
| 2017 | -21.00% | -31733.48% | 0.00x | 1.05x | Skr-106.34 Million |
| 2018 | -31.37% | 0.00% | 0.00x | 1.09x | Skr-109.63 Million |
| 2019 | -154.02% | 0.00% | 0.00x | 1.40x | Skr-172.07 Million |
| 2020 | -283.91% | -509.15% | 0.25x | 2.23x | Skr-195.65 Million |
| 2021 | -62.93% | -893.70% | 0.06x | 1.26x | Skr-232.07 Million |
| 2022 | -100.83% | -1248.68% | 0.06x | 1.35x | Skr-175.64 Million |
| 2023 | -30.53% | -5141.61% | 0.01x | 1.16x | Skr-49.21 Million |
| 2024 | -55.79% | 0.00% | 0.00x | 1.26x | Skr-51.28 Million |
| 2025 | -50.22% | 0.00% | 0.00x | 1.20x | Skr-64.96 Million |
Industry Comparison
This section compares Isofol Medical AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Isofol Medical AB (ISOFOL) | Skr107.87 Million | -134.42% | 0.20x | $13.56 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |